Abstract
Positron emission tomography/computed tomography (PET/CT) is a frequently used imaging method for the characterization of pulmonary nodules, primary staging of thoracic tumors, assessment of treatment response and detection of residual/recurrent disease. PET/magnetic resonance imaging (MRI), as a new imaging modality, has some advantages for the evaluation of soft tissue tumors with its lower ionizing radiation dose and multiparametric evaluation opportunities. However, due to the technical limitations of MRI in lung parenchyma, its role in the evaluation of millimetric lung nodules and local staging of lung cancer is controversial. Nevertheless, previous studies show that PET/MRI generally has a similar diagnostic performance to PET/CT in the primary staging of lung cancer. PET/MRI also makes some contributions to local and distant metastatic staging and to determination of tumor resectability. The combination of PET and functional MRI parameters reflecting different biological characteristics of the tumor may provide new biomarkers for the earlier assessment of treatment response and the prediction of survival. Furthermore, newly developed MRI sequences increase the sensitivity of imaging modality in the detection of millimetric pulmonary nodules. PET/MRI has also high diagnostic accuracy in local staging of malignant pleural mesothelioma and thymic epithelial tumors. In this review, it is aimed to evaluate the diagnostic role and the contribution of PET/MRI in thoracic tumors.
Keywords: Positron emission tomography, magnetic resonance imaging, pulmonary nodule, lung cancer, malignant pleural mesothelioma, thymic epithelial tumor
References
Kovács Á, Sipos D, Lukács G, et al. A PET/CT szerepe a sugárkezelésre kerülő betegek N és M klinikai stagingjében, a terápia meghatározásában. Intézeti tapasztalatok [The predictive role of PET/CT imaging in clinical N and M staging and treatment decision process. Institutional experiences in Hungary]. Orv Hetil. 2018;159:1593-1601.
Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients. J Nucl Med. 2016;57:420-430.
Bergin CJ, Glover GM, Pauly J. Magnetic resonance imaging of lung parenchyma. J Thorac Imaging. 1993;8:12-17.
Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines. Chest. 2007;132:94S-107S.
Martin MD, Henry TS, Berry MF, et al. ACR Appropriateness Criteria® incidentally detected indeterminate pulmonary nodule. J Am Coll Radiol. 2023;20:S455-S470.
Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008;246:772-782.
Salavati A, Borofsky S, Boon-Keng TK, et al. Application of partial volume effect correction and 4D PET in the quantification of FDG avid lung lesions. Mol Imaging Biol. 2015;17:140-148.
Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA. 2014;312:1227-1236.
Chandarana H, Heacock L, Rakheja R, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology. 2013;268:874-881.
Rauscher I, Eiber M, Fürst S, et al. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med. 2014;55:724-729.
Owens C, Hindocha S, Lee R, Millard T, Sharma B. The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives. Br J Radiol. 2023;96:20220339.
Raad RA, Friedman KP, Heacock L, Ponzo F, Melsaether A, Chandarana H. Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy. J Magn Reson Imaging. 2016;43:504-511.
Sawicki LM, Grueneisen J, Buchbender C, et al. Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies. J Nucl Med. 2016;57:15-20.
de Galiza Barbosa F, Geismar JH, Delso G, et al. Pulmonary nodule detection in oncological patients–Value of respiratory-triggered, periodically rotated overlapping parallel T2-weighted imaging evaluated with PET/CT-MR. Eur J Radiol. 2018;98:165-170.
Ma W, Sheikh K, Svenningsen S, et al. Ultra‐short echo‐time pulmonary MRI: Evaluation and reproducibility in COPD subjects with and without bronchiectasis. J Magn Reson Imaging. 2015;41:1465-1474.
Gibiino F, Sacolick L, Menini A, Landini L, Wiesinger F. Free-breathing, zero-TE MR lung imaging. MAGMA. 2015;28:207-215.
Burris NS, Johnson KM, Larson PE, et al. Detection of small pulmonary nodules with ultrashort echo time sequences in oncology patients by using a PET/MR system. Radiology. 2016;278:239-246.
Bae K, Jeon KN, Hwang MJ, et al. Comparison of lung imaging using three-dimensional ultrashort echo time and zero echo time sequences: preliminary study. Eur Radiol. 2019;29:2253-2262.
Zeng F, Nogami M, Ueno YR, et al. Diagnostic performance of zero-TE lung MR imaging in FDG PET/MRI for pulmonary malignancies. Eur Radiol. 2020;30:4995-5003.
Cavion CC, Altmayer S, Forte GC, et al. Diagnostic performance of MRI for the detection of pulmonary nodules: a systematic review and meta-analysis. Radiol Cardiothorac Imaging. 2024;6:e230241.
Ohno Y, Takenaka D, Yoshikawa T, et al. Efficacy of ultrashort echo time pulmonary MRI for lung nodule detection and lung-RADS classification. Radiology. 2022;302:697-706.
Chelala L, Hossain R, Kazerooni EA, Christensen JD, Dyer DS, White CS. Lung-RADS version 1.1: challenges and a look ahead, from the AJR special series on radiology reporting and data systems. AJR Am J Roentgenol. 2021;216:1411-1422.
Li Q, Zhu L, Stackelberg Ov, et al. MRI compared with low-dose CT for incidental lung nodule detection in COPD: A multicenter trial. Radiol Cardiothorac Imaging. 2023;5:e220176.
Wang X, Cui Y, Wang Y, et al. Assessment of lung nodule detection and lung CT screening reporting and data system classification using zero echo time pulmonary MRI. J Magn Reson Imaging. 2024.
Liu Q, Feng Z, Liu WV, et al. Assessment of solid pulmonary nodules or masses using zero echo time MR lung imaging: a prospective head-to-head comparison with CT. Front Oncol. 2022;12:812014.
Hinsen M, Nagel AM, May MS, Wiesmueller M, Uder M, Heiss R. Lung nodule detection with modern low-field MRI (0.55 T) in comparison to CT. Invest Radiol. 2024;59:215-222.
Bae K, Jeon KN, Hwang MJ, et al. Respiratory motion–resolved four-dimensional zero echo time (4D ZTE) lung MRI using retrospective soft gating: feasibility and image quality compared with 3D ZTE. Eur Radiol. 2020;30:5130-5138.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584-594.
Van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-1755.
Strange CD, Strange TA, Erasmus LT, et al. Imaging in Lung Cancer Staging. Clin Chest Med. 2024;45:295-305.
Ettinger DS, Wood DE, Akerley W, et al. NCCN Guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14:255-264.
Li Y, Jin G, Su D. Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies. Oncotarget. 2017;8:35743-35749.
Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16:1171-1182.
Ravenel JG, Rosenzweig KE, Kirsch J, et al. ACR appropriateness criteria non-invasive clinical staging of bronchogenic carcinoma. J Am Coll Radiol. 2014;11:849-856.
Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S-e250S.
Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non–small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879-892.
Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22:151-155.
Azad A, Chionh F, Scott AM, et al. High impact of 18 F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol. 2010;12:443-451.
Gregory DL, Hicks RJ, Hogg A, et al. Effect of PET/CT on management of patients with non–small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53:1007-1015.
Li Z, Sun D, Li A, Shu Y. Head-to-head comparison of [18F] FDG PET/MRI and [18F] FDG PET/CT for TNM staging in non-small cell lung cancer: a systematic review and meta-analysis. Clin Transl Imaging. 2024;12:413-421.
Mirshahvalad SA, Metser U, Basso Dias A, Ortega C, Yeung J, Veit-Haibach P. 18F-FDG PET/MRI in detection of pulmonary malignancies: a systematic review and meta-analysis. Radiology. 2023;307:e221598.
Groheux D, Quere G, Blanc E, et al. FDG PET-CT for solitary pulmonary nodule and lung cancer: literature review. Diagn Interv Imaging. 2016;97:1003-1017.
Yang RM, Li L, Wei XH, et al. Differentiation of central lung cancer from atelectasis: comparison of diffusion-weighted MRI with PET/CT. PLoS One. 2013;8:e60279.
Sorace AG, Elkassem AA, Galgano SJ, et al. Imaging for response assessment in cancer clinical trials. Semin Nucl Med. 2020;50:488-504.
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401-407.
Schaarschmidt BM, Grueneisen J, Metzenmacher M, et al. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT? Eur Radiol. 2017;27:681-688.
Kirchner J, Sawicki LM, Nensa F, et al. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:437-445.
Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. Semin Nucl Med. 2015;45:268-281.
Fraioli F, Screaton NJ, Janes SM, et al. Non-small-cell lung cancer resectability: diagnostic value of PET/MR. Eur J Nucl Med Mol Imaging. 2015;42:49-55.
Kim H, Goo JM, Kim YT, Park CM. CT-defined visceral pleural invasion in T1 lung adenocarcinoma: lack of relationship to disease-free survival. Radiology. 2019;292:741-749.
Wang ML, Zhang H, Yu HJ, et al. An initial study on the comparison of diagnostic performance of 18F-FDG PET/MR and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer: Focus on pleural invasion. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2023;42:16-23.
Zhang A, Meng X, Yao Y, et al. Predictive value of 18 F-FDG PET/MRI for pleural invasion in solid and subsolid lung adenocarcinomas smaller than 3 cm. J Magn Reson Imaging. 2023;57:1367-1375.
Zhang Y, Kwon W, Lee HY, et al. Imaging assessment of visceral pleural surface invasion by lung cancer: comparison of CT and contrast-enhanced radial T1-weighted gradient echo 3-Tesla MRI. Korean J Radiol. 2021;22:829-839.
Ohno Y, Koyama H, Lee HY, Yoshikawa T, Sugimura K. Magnetic resonance imaging (MRI) and positron emission tomography (PET)/MRI for lung cancer staging. J Thorac Imaging. 2016;31:215-227.
Shen G, Lan Y, Zhang K, Ren P, Jia Z. Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis. PLoS One. 2017;12:e0173104.
Zhang M, Yang W, Yuan Y, et al. Diagnostic potential of [18F] FDG PET/MRI in non-small cell lung cancer lymph node metastasis: a meta-analysis. Jpn J of Radiol. 2024;42:87-95.
Zhang M, Liu Z, Yuan Y, et al. Head-to-head comparison of 18F-FDG PET/CT and 18F-FDG PET/MRI for lymph node metastasis staging in non-small cell lung cancer: a meta-analysis. Diagn Interv Radiol. 2024;30:99-106.
Mirshahvalad SA, Kohan A, Metser U, et al. Diagnostic performance of whole-body [18F] FDG PET/MR in cancer M staging: a systematic review and meta-analysis. Eur Radiol. 2024;34:673-685.
Lee HY, Lee KS, Kim BT, et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci. 2009;24:1132-1138.
Ohno Y, Koyama H, Onishi Y, et al. Non–small cell lung cancer: whole-body MR examination for M-stage assessment—utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008;248:643-654.
Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non‐small cell lung cancer patients: Comparison of whole‐body diffusion‐weighted imaging (DWI), whole‐body MR imaging without and with DWI, whole‐body FDG‐PET/CT, and bone scintigraphy. J Magn Reson Imaging. 2009;30:298-308.
Ohno Y, Yoshikawa T, Takenaka D, et al. Small cell lung cancer staging: prospective comparison of conventional staging tests, FDG PET/CT, whole-body MRI, and coregistered FDG PET/MRI. AJR Am J Roentgenol. 2022;218:899-908.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S.
Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24:843-847.
Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology. 2011;261:182-192.
Weiss E, Ford JC, Olsen KM, et al. Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study. Lung Cancer. 2016;96:113-119.
Liu J, Lv H, Dong J, et al. Diffusion-weighted magnetic resonance imaging for early detection of chemotherapy resistance in non-small cell lung cancer. Med Sci Monit. 2019;25:6264-6270.
Regier M, Derlin T, Schwarz D, et al. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol. 2012;81:2913-2918.
Ohno Y, Koyama H, Yoshikawa T, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non–small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol. 2012;198:75-82.
Tsuchida T, Morikawa M, Demura Y, Umeda Y, Okazawa H, Kimura H. Imaging the early response to chemotherapy in advanced lung cancer with diffusion‐weighted magnetic resonance imaging compared to fluorine‐18 fluorodeoxyglucose positron emission tomography and computed tomography. J Magn Reson Imaging. 2013;38:80-88.
Iizuka Y, Matsuo Y, Umeoka S, et al. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and 18F-FDG PET. Eur J Radiol. 2014;83:2087-2092.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627-1639.
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123-135.
Umeda Y, Morikawa M, Anzai M, et al. Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer. J Immunother Cancer. 2020;8:e000349.
Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy. Eur J Nucl Med Mol Imaging. 2019;46:238-250.
Munoz-Schuffenegger P, Kandel S, Alibhai Z, et al. A prospective study of magnetic resonance imaging assessment of post-radiation changes following stereotactic body radiation therapy for non-small cell lung cancer. Clin Oncol. 2019;31:720-727.
He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol. 2014;55:309-317.
Hiriart E, Deepe R, Wessels A. Mesothelium and malignant mesothelioma. J Dev Biol. 2019;7:7.
Strange CD, Shroff GS, Ahuja J, Vlahos I, Benveniste MFK, Truong MT. Imaging of Malignant Pleural Mesothelioma: Pearls and Pitfalls. Semin Ultrasound CT MR. 2021;42:542-551.
Truong MT, Viswanathan C, Godoy MB, Carter BW, Marom EM. Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations. Semin Roentgenol. 2013;48:323-334.
Plathow C, Staab A, Schmaehl A, et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol. 2008;43:737-744.
Incerti E, Broggi S, Fodor A, et al. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. Eur J Nucl Med Mol Imaging. 2018;45:2071-2078.
Kindler HL, Ismaila N, Armato III SG, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1343-1373.
Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039-1047.
Szczyrek M, Bitkowska P, Jutrzenka M, Szudy-Szczyrek A, Drelich-Zbroja A, Milanowski J. Pleural neoplasms-what could MRI change? Cancers (Basel). 2023;15:3261.
Gill RR, Umeoka S, Mamata H, et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol. 2010;195:W125-W130.
Coolen J, De Keyzer F, Nafteux P, et al. Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging. Radiology. 2015;274:576-584.
Schaarschmidt BM, Sawicki LM, Gomez B, et al. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging. Clin Imaging. 2016;40:956-960.
Murphy DJ, Mak SM, Mallia A, et al. Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. Eur J Radiol. 2019;115:46-52.
Armato SG 3rd, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1). J Thorac Oncol. 2018;13:1012-1021.
Gill RR, Naidich DP, Mitchell A, et al. North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study. J Thorac Oncol. 2016;11:1335-1344.
Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449-1458.
Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787-2794.
Kanemura S, Kuribayashi K, Funaguchi N, et al. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 2017;86:92-98.
Kitajima K, Kuribayashi K, Minami T, et al. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. Oncotarget. 2024;15:408-417.
Vivoda Tomšič M, Bisdas S, Kovač V, Serša I, Šurlan Popovič K. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria. Cancer Imaging. 2019;19:1-11.
Moon JW, Lee KS, Shin M-H, et al. Thymic epithelial tumors: prognostic determinants among clinical, histopathologic, and computed tomography findings. Ann Thorac Surg. 2015;99:462-470.
Marx A, Ströbel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014;9:596-611.
Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow‐up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-2492.
Bhora FY, Chen DJ, Detterbeck FC, et al. The ITMIG/IASLC thymic epithelial tumors staging project: a proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S88-S96.
Strange CD, Ahuja J, Shroff GS, Truong MT, Marom EM. Imaging evaluation of thymoma and thymic carcinoma. Front Oncol. 2022;11:810419.
Benveniste MF, Moran CA, Mawlawi O, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. 2013;8:502-510.
Ohno Y, Kishida Y, Seki S, et al. Comparison of interobserver agreement and diagnostic accuracy for IASLC/ITMIG thymic epithelial tumor staging among co-registered FDG-PET/MRI, whole-body MRI, integrated FDG-PET/CT, and conventional imaging examination with and without contrast media administrations. Acad Radiol. 2022;29:S122-S131.
Sugawara H, Ito K, Watanabe H, et al. Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses. Nucl Med Commun. 2022;43:92-99.
Veit-Haibach P, Ahlström H, Boellaard R, et al. International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology. Eur J Nucl Med Mol Imaging. 2023;50:3513-3537.
